|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Aim:</b> Nowadays, IFN-α is considered a promising therapeutic target for systemic lupus erythematosus.
|
31724446 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Peg-IFN combined with TDF may increase the virological response rate, biochemical response rate, and HBsAg loss rate in patients with CHB infection.
|
31114265 |
2019 |
|
Virus Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Conclusions:</b> Dysregulated expression of IFN-dependent pathways after respiratory viral infections is a defining immunophenotypic feature of AVB-susceptible infants and a subset of children.
|
30562046 |
2019 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Methods:</b> We investigated the sPD-L1 levels in the sera of 80 genotype 1b Japanese patients with CHC who underwent 12 weeks of telaprevir (TVR)- or simeprevir (SMV)-based triple therapy followed by 12 weeks of dual therapy with pegylated IFN-α plus ribavirin.
|
28539815 |
2017 |
|
Takayasu Arteritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>Aim</i>: To investigate the relation between polymorphisms in the interleukin 10 (<i>IL</i>)-<i>10</i>, tumor necrosis factor (<i>TNF)</i>-α, transforming growth factor (<i>TGF)-</i>β and interferon (<i>IFN)-γ</i> genes and Takayasu's arteritis in the Mexican population.
|
31816847 |
2019 |
|
Behcet's uveitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>Conclusion</i>: IFN-α seems an effective and safe treatment option in the management of refractory BU.
|
31161949 |
2019 |
|
Influenza
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<i>cpIFNA1</i> will enable us to perform a proof-of-concept experiment to verify that IFN-Alpha1 AS increases <i>cpIFNA1</i> mRNA levels, resulting in inhibition of influenza virus proliferation <i>in vivo</i>.
|
30844713 |
2019 |
|
Pneumonia
|
0.050 |
Biomarker
|
disease |
BEFREE |
<i>In vivo</i>, ExoT also increases IFN-γ levels and the percentage of IFN-γ<sup>+</sup> NK cells in lungs during PA pneumonia, confirming <i>in vitro</i> data.
|
29067027 |
2017 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
(Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients.
|
30715261 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
(Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients.
|
30715261 |
2019 |
|
Systemic Scleroderma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
.To examine whether myxovirus-resistance protein A (MxA) mRNA expression, commonly considered a reliable marker of Type I interferon (IFN) bioactivity, is modified in patients with systemic sclerosis (SSc); if it is associated to specific clinical features; and if its modulation is accompanied by modulation of mRNA for the Type I IFN receptor (IFNAR).
|
18843779 |
2008 |
|
Lupus Vulgaris
|
0.100 |
Biomarker
|
disease |
BEFREE |
10-week old female lupus-prone (NZM2328), wild-type (BALB/c) and iNZM mice (lack a functional type I IFN receptor on NZM2328 background) were treated on their dorsal skin with 100 mJ/cm<sup>2</sup> of UVB for 5 consecutive days.
|
31248690 |
2019 |
|
Lupus Erythematosus, Discoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
10-week old female lupus-prone (NZM2328), wild-type (BALB/c) and iNZM mice (lack a functional type I IFN receptor on NZM2328 background) were treated on their dorsal skin with 100 mJ/cm<sup>2</sup> of UVB for 5 consecutive days.
|
31248690 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
10-week old female lupus-prone (NZM2328), wild-type (BALB/c) and iNZM mice (lack a functional type I IFN receptor on NZM2328 background) were treated on their dorsal skin with 100 mJ/cm<sup>2</sup> of UVB for 5 consecutive days.
|
31248690 |
2019 |
|
Lupus Erythematosus
|
0.100 |
Biomarker
|
disease |
BEFREE |
10-week old female lupus-prone (NZM2328), wild-type (BALB/c) and iNZM mice (lack a functional type I IFN receptor on NZM2328 background) were treated on their dorsal skin with 100 mJ/cm<sup>2</sup> of UVB for 5 consecutive days.
|
31248690 |
2019 |
|
Osteosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
2 -ME induces IFN gene activity and expression in osteosarcoma cells.
|
22429849 |
2012 |
|
Osteosarcoma of bone
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
2 -ME induces IFN gene activity and expression in osteosarcoma cells.
|
22429849 |
2012 |
|
Childhood Osteosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
2 -ME induces IFN gene activity and expression in osteosarcoma cells.
|
22429849 |
2012 |
|
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
2'-5' oligoadenylate synthetase is stimulated by dsRNA to produce 5'-phosphorylated, 2'-5'-linked oligoadenylates (2-5A), whose function is to activate RNase L. Although RNase L is required for a complete IFN antiviral response and mutations in the RNase L gene (RNASEL or HPC1) increase prostate cancer rates, it is unknown how 2-5A affects these biological endpoints through its receptor, RNase L. Presently, we show that 2-5A activation of RNase L produces a remarkable stimulation of transcription (>/=20-fold) for genes that suppress virus replication and prostate cancer.
|
16203993 |
2005 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
2'-5' oligoadenylate synthetase is stimulated by dsRNA to produce 5'-phosphorylated, 2'-5'-linked oligoadenylates (2-5A), whose function is to activate RNase L. Although RNase L is required for a complete IFN antiviral response and mutations in the RNase L gene (RNASEL or HPC1) increase prostate cancer rates, it is unknown how 2-5A affects these biological endpoints through its receptor, RNase L. Presently, we show that 2-5A activation of RNase L produces a remarkable stimulation of transcription (>/=20-fold) for genes that suppress virus replication and prostate cancer.
|
16203993 |
2005 |
|
Squamous cell carcinoma of the head and neck
|
0.040 |
Biomarker
|
disease |
BEFREE |
5-aza repressed expression and activity of matrix metalloproteinases (MMP) in HPV<sup>+</sup> HNSCC, activated IFN response in some HPV<sup>+</sup> head and neck cancer cells, and inhibited the ability of HPV<sup>+</sup> xenografted tumors to invade mouse blood vessels.<b>Conclusions:</b> 5-aza may provide effective therapy for HPV-associated HNSCC as an alternative or complement to standard cytotoxic therapy.<i></i>.
|
28916527 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
62 patients with HCV genotype 1 and HIV-1 who were HCV treatment-naive and receiving 0 or 1 of 2 antiretroviral regimens were randomly assigned to TVR plus PEG-IFN-α2a-ribavirin or placebo plus PEG-IFN-α2a-ribavirin for 12 weeks, plus 36 weeks of PEG-IFN-α2a-ribavirin.
|
23685940 |
2013 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hepatitis C virus (HCV) infection is remarkable by its ability to evade host antiviral defenses; however, there is little information as to whether endogenous IFN is activated or not in this disease.
|
10347136 |
1999 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Leukemias with a -5/del(5q) have a higher expression of genes involved in cell cycle control (CCNA2, CCNE2, CDC2), checkpoints (BUB1), or growth (MYC), and loss of expression of the gene encoding IFN consensus sequence-binding protein (ICSBP).
|
12417757 |
2002 |
|
Rhinovirus infection
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Rhinovirus induces airway epithelial gene expression through double-stranded RNA and IFN-dependent pathways.
|
16210696 |
2006 |